Imunon, Inc. Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
Imunon, Inc. (IMNN) had Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount of $0 as of 2017-03-31, per its 10-Q filed 2017-08-14.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount · last filed 2017-08-14
- 2017-03-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2016-12-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2015-12-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2014-12-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2017-03-31 | $0.00 10-Q · filed 2017-08-14 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-24 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-24 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-10 |
| 2014-06-30 | $0.00 10-Q · filed 2014-08-07 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |